Yuancheng (Ryan) Lu at ARDD2026: Functional Genomics and Virtual Screening

Value of the Information & Strength of the Argument

The talk provides substantial value by presenting two novel, data-driven approaches to identify rejuvenation factors, moving beyond the informed guess of OSK. The argumentation is solid, supported by experimental evidence: vision tracking, ERG recordings, grip strength tests, and molecular analyses. The speaker clearly explains the logic behind each screen, the rationale for choosing the eye model, and provides specific examples (GST4, NKX2-5) with quantitative outcomes. The discussion of engineering NKX2-5 to reduce toxicity demonstrates a rigorous understanding of the underlying biology. The argument for virtual screening is compelling, emphasizing the need for perturbation datasets and human-relevant predictions, though it is presented as an ongoing effort.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high; the speaker presents original unpublished or preprint results, with detailed methodological details and appropriate caveats. He acknowledges limitations such as the need for validation and the use of aging clocks. The title accurately describes the content: a focus on functional genomics and virtual screening. Sources cited include the conference organization (agingpharma.org) and its LinkedIn page, which are part of the description. No external papers are explicitly referenced, but the talk mentions preprints and established techniques. The title-content alignment is excellent, and the presentation is well-structured.

The title accurately reflects the content: functional genomics and virtual screening for rejuvenation factor discovery.

8/10

Presentation of original research at a specialized conference, with detailed methodology and results. Some results are preliminary or preprints.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction to the eye as a model, age-related eye diseases, and advantages of vision testing.
• 02:30Explanation of vision tracking in mice and the OSK proof-of-concept in reversing aging signs.
• 05:00First story: functional genomics to find downstream factors of OSK, discovery of GST4 and its effect on clearing oxidative damage.
• 07:30Second story: unbiased ORF screen in RPE cells, identification of NKX2-5 as a robust rejuvenation factor.
• 10:00Engineering NKX2-5 by removing the homeodomain to eliminate toxicity, with vision improvements and long-term effects.
• 12:30Beyond the eye: whole-body effects of NKX2-5, grip strength and frailty index improvements in mice.
• 15:00Virtual screening using single-cell foundation models and human longitudinal datasets, ongoing validation.
• 17:30Summary and future directions: gene therapy, iPS-derived cell therapy, and the potential for rejuvenation factors.

• AgingPharma.org — Official ARDD conference website, mentioned in the description.
• ARDD LinkedIn — Conference LinkedIn page, mentioned in the description.